Krane Funds Advisors LLC Invests $512,000 in Merck & Co., Inc. (NYSE:MRK)

Krane Funds Advisors LLC acquired a new stake in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) in the fourth quarter, HoldingsChannel reports. The firm acquired 6,685 shares of the company’s stock, valued at approximately $512,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Aviva PLC boosted its holdings in Merck & Co., Inc. by 11.2% during the 4th quarter. Aviva PLC now owns 2,110,672 shares of the company’s stock valued at $161,762,000 after acquiring an additional 213,185 shares during the period. Coastline Trust Co boosted its holdings in Merck & Co., Inc. by 0.7% during the 4th quarter. Coastline Trust Co now owns 47,260 shares of the company’s stock valued at $3,622,000 after acquiring an additional 330 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in Merck & Co., Inc. during the 4th quarter valued at $851,000. Tsfg LLC boosted its holdings in Merck & Co., Inc. by 5.7% during the 4th quarter. Tsfg LLC now owns 5,785 shares of the company’s stock valued at $443,000 after acquiring an additional 312 shares during the period. Finally, Allen Investment Management LLC boosted its holdings in Merck & Co., Inc. by 144.4% during the 4th quarter. Allen Investment Management LLC now owns 39,038 shares of the company’s stock valued at $2,992,000 after acquiring an additional 23,068 shares during the period. Institutional investors own 72.88% of the company’s stock.

NYSE:MRK traded down $0.15 during mid-day trading on Tuesday, hitting $87.49. 710,273 shares of the company’s stock traded hands, compared to its average volume of 12,126,637. The company has a fifty day moving average of $82.99 and a 200 day moving average of $80.47. Merck & Co., Inc. has a twelve month low of $70.89 and a twelve month high of $91.40. The company has a market capitalization of $221.16 billion, a P/E ratio of 15.81, a P/E/G ratio of 1.19 and a beta of 0.37. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.02 and a current ratio of 1.27.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.31. Merck & Co., Inc. had a return on equity of 49.57% and a net margin of 26.27%. The company had revenue of $15.90 billion for the quarter, compared to analyst estimates of $14.64 billion. The firm’s quarterly revenue was up 31.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.40 EPS. On average, research analysts expect that Merck & Co., Inc. will post 7.31 earnings per share for the current fiscal year.

A number of equities research analysts have weighed in on MRK shares. Barclays lifted their target price on Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. Morgan Stanley decreased their target price on Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 6th. SVB Leerink decreased their target price on Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating for the company in a research report on Thursday, April 21st. JPMorgan Chase & Co. decreased their target price on Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating for the company in a research report on Friday, January 28th. Finally, StockNews.com began coverage on Merck & Co., Inc. in a research report on Thursday, March 31st. They set a “strong-buy” rating for the company. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $90.69.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.